Director, Chief R&D Commercial Officer · RECURSION PHARMACEUTICALS, INC. · Class A Common Stock
Side
F
Value
$73K
Shares
17.6K
Price
$4.14
Executed
Nov 17, 2025
Disclosed
Nov 19, 2025
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 17 executedNov 19, 2025 disclosed
RXRX · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Tax withholding — administrative, little informational value
Relative size+4 / 25
$73K reported value · 2.4% of prior position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Khan Najat filed this Form 4 reporting a tax withholding of RXRX on Nov 17, 2025. It became public on Nov 19, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director, Chief R&D Commercial Officer
Khan Najatcik:0002020969
Issuer
RECURSION PHARMACEUTICALS, INC.cik:0001601830
Revision history · 0
No field has changed since this record was first ingested.
